CRIZLIEVA 250MG ( Crizotinib Tablets 250mg )

CRIZLIEVA 250 mg contains Crizotinib, an oral tyrosine kinase inhibitor (TKI). It targets ALK (anaplastic lymphoma kinase), ROS1, and MET receptors, inhibiting signaling pathways that drive tumor cell growth and survival. It is especially effective in ALK-positive and ROS1-positive lung cancers.

Crizotinib is indicated for:

1. Metastatic Non-Small Cell Lung Cancer (NSCLC)
    – ALK-positive disease
    – ROS1-positive disease

Common side effects:

    •  Visual disturbances (blurred vision, photopsia)

    •  Nausea, vomiting, diarrhea

    •  Fatigue

    •  Edema

Laboratory abnormalities:

    •  Elevated liver enzymes

Serious side effects:

    •  Hepatotoxicity

    •  QT interval prolongation

    •  Interstitial lung disease (rare)

    •  Bradycardia

 Regular monitoring of LFTs, ECG, and heart rate is advised.

Standard adult dose:

    •  250 mg twice daily

 Continue treatment until disease progression or unacceptable toxicity.

NOTE: This medicine should be taken only under a doctor’s supervision.